Skip to content

Medicinal Mushroom Extract Characterization SOPs

Draft methods for identity, extraction, chemical characterization, and functional verification. No analytical tolerance or acceptance threshold has been established; each must be set from method qualification before result-bearing use.

SOPs

SOP-1 — Ganoderma lingzhi GLPP Polysaccharide-Peptide Fractionation (load-bearing)

Status: Stub — the exact upstream cultivation, extraction, and fractionation protocol still requires primary-source recovery and method qualification.

Source material: an authenticated G. lingzhi material with strain/accession, source, substrate, harvest state, and storage history recorded. No unique acceptable commercial strain has been established.

Planned method (extrapolated from English-language pharmacology papers — needs CNKI-sourced upstream protocol verification): 1. Hot water extraction of dried mycelium (or freeze-dried fruiting body), 90°C, 2 hr, water:biomass = 10:1 2. Centrifugation + concentration of supernatant under vacuum 3. Ethanol precipitation (4 vol EtOH, 4°C overnight) → polysaccharide-peptide fraction 4. DEAE-Sepharose anion-exchange chromatography → fraction by charge profile 5. Sephacryl S-500 size-exclusion chromatography → MW-based separation 6. SEC-MALS verification of molecular-weight distribution. The HUA-active GLPP fraction remains unresolved: related papers report materially different bulk and post-fractionation sizes, and those preparations are not interchangeable. 7. Amino acid analysis (peptide composition) 8. Glycan linkage NMR fingerprint

Primary-source prerequisite: recover and verify the exact cultivation, extraction, and fractionation methods for the material whose biological result is being tested. The historical search notes are query aids, not method authority.

Acceptance criteria: unset until the method's precision, recovery, specificity, and between-operator variance are measured.

SOP-2 — Cordyceps militaris Cordycepin + Pentostatin HPLC Quantification

Source material: an authenticated C. militaris fruiting-body or mycelial material with strain/accession and cultivation configuration recorded. Historical yield ranks do not select the material.

Xiong et al. 2024 reports a whole C. militaris water extract in potassium-oxonate + yeast-paste hyperuricemia rats. The publisher page reports that material as 35.86% polysaccharides, 27.05% protein, 0.21% phenolics, and 0.83% cordycepin. The biological result therefore cannot be assigned to cordycepin alone: SOP-2 should quantify cordycepin while retaining total polysaccharide/protein and, where feasible, pentostatin in the batch fingerprint (Animal Model for the whole-extract result).

Planned method (Wang 2014 with Xia 2017 cluster diagnostic ratio): 1. Aqueous extraction of dried biomass, 80°C, 1 hr 2. C18 SPE cleanup 3. RP-HPLC, C18 column, water-methanol gradient 4. UV detection at 260 nm 5. Co-quantify: cordycepin (3'-deoxyadenosine), adenosine (precursor + ADA-deamination context), pentostatin (the natural ADA-inhibitor co-product per Xia 2017 PMID 29056419) 6. Record the pentostatin:cordycepin ratio as batch-identity data. Co-production does not make the ratio a diagnostic of full-cluster expression, protection, exposure, efficacy, or clinical positioning without direct validation. 7. Reference standards: cordycepin ≥98% HPLC purity (Sigma C3394 or equivalent) and pentostatin (Cayman 14878 or equivalent). Source and handle both under applicable institutional research-use and chemical-safety requirements.

Acceptance criteria: unset until cordycepin and pentostatin recovery, specificity, calibration, detection limits, and inter-operator precision are measured.

SOP-3 — Pleurotus citrinopileatus Ergothioneine HILIC-HPLC Quantification

Source material: authenticated dried P. citrinopileatus fruiting body. One reported material contained 7.0 mg/g dry weight; that exact configuration is a calibration lead, not a cross-species production rank.

Planned method (Cohen 2014 with HILIC modification for polar zwitterion): 1. UA-DES (urea-based deep eutectic solvent) or aqueous methanol extraction 2. HILIC chromatography (suitable for polar zwitterionic EGT — reverse-phase fails for this analyte) 3. UV detection at 254 nm (or LC-MS for sensitivity) 4. Stable-isotope-labeled internal standard (²H₉-ergothioneine) for absolute quantification 5. Calibration: 0.1-10 mg/g range covers dietary-relevant content

Acceptance criteria: unset until extraction recovery, matrix effects, calibration, detection limits, and inter-operator precision are measured against the exact material.

SOP-4 — Functional Verification Readouts

For each compound, a downstream functional readout that confirms bioactivity beyond chemical identification:

  • GLPP — proposed ADA test: qualify one exact fraction, then measure ADA-driven substrate/product conversion directly with interference controls. The ADA mechanism is a hypothesis, not an established property of generic GLPP.
  • Cordycepin — renal transport test: use a polarized urate-transport assay with transporter attribution; keep URAT1 expression as a secondary readout rather than the functional gate.
  • Ergothioneine — gout-inflammation test: choose a primary-source-grounded exposure range, then measure a prespecified MSU-relevant functional endpoint with Nrf2/redox readouts as mechanism probes.

Acceptance criteria: preregister after pilot estimates establish assay variance, viability bounds, and the smallest effect that would change the decision.

SOP-6 — Tiered methodology framework

The SOPs above are unvalidated bench-method candidates. The quantification ladder can organize method development, but a lower-cost readout becomes a batch-control method only after it is validated against a qualified analytical anchor for the exact material.

The quantification ladder defines the shared four tiers. This SOP supplies mushroom-specific assays and calibration anchors; enzyme-quantification-protocol.md supplies the koji-enzyme methods. First-batch values do not yet exist. GLPP requires Tier 3 SEC-MALS, and the proposed cordycepin Tier 2 diazo method remains speculative pending primary-literature and bench validation.

Material Tier 1 observation Tier 2 candidate screen Tier 3 analytical anchor Tier 4 qualified external method
Cordycepin material Record mass, moisture, extraction yield, and appearance; no compound inference Candidate UV/color method must first pass specificity, recovery, and cross-reactivity against the Tier 3 anchor SOP-2 candidate HPLC/LC-MS method with reference standards Qualified external chromatography when required
Ergothioneine material Record mass, moisture, extraction yield, and appearance; no compound inference Candidate thiol/color method must first show that matrix interferents do not dominate SOP-3 candidate HILIC-LC/MS method with internal standard Qualified external HILIC-LC/MS when required
GLPP material Record mass and extraction yield; not GLPP-specific Total-polysaccharide assays may track a batch only after correlation with the exact fraction is validated SOP-1 candidate SEC-MALS plus composition methods Qualified external fraction-characterization method when required

Operational pattern (the calibrate-once-track-batches workflow):

  1. Initial Tier 3 calibration — quantify a reference batch by SOP-½/3 above. Anchor numbers: mg/g extract for each target compound; document extract source, batch ID, lot, harvest details.
  2. Batch tracking at Tier 2 — use a lower-cost readout only after the validation study defines its acceptable agreement and scope.
  3. Tier 1 observation — record process and mass-balance variables only; do not infer concentration, dose, or biological activity.
  4. Tier 4 outsourced — only invoked if regulatory submission requires it. Adds GLP/GMP overhead but uses the same analytical chemistry as Tier 3.

Operational boundary: method-transfer cost matters, but it cannot be solved by declaring a low-cost proxy valid. Recalibrate whenever strain, substrate, culture, extraction, matrix, or assay leaves the validated scope.

Substrate-accumulated vs biosynthesized compounds

Not all compounds detected in a mushroom extract are produced by the fungus. Substrate-accumulated compounds pass through from the cultivation substrate (e.g., plant flavonoids from oak sawdust) and concentrate in mycelium without being biosynthesized by fungal metabolism. Biosynthesized compounds are produced by the fungal genome's secondary-metabolite biosynthetic gene clusters (BGCs). The two have fundamentally different batch-variability profiles:

Compound Origin Dominant batch-variance source
Cordycepin (C. militaris) Biosynthesized (cns1+cns2 BGC) Strain genetics + fermentation conditions
Ergothioneine (Pleurotus / koji) Biosynthesized (egtBCD pathway) Strain genetics + substrate sulfur availability
GLPP (G. lucidum) Biosynthesized (mycelium-specific polysaccharide-peptide) Strain genetics + cultivation stage
Kojic acid (A. oryzae) Biosynthesized Strain genetics + carbon source
Quercetin, genistein, daidzein, morin (in mushroom extracts) Substrate-accumulated (plant flavonoids passed through) Substrate lot + source (oak sawdust species, geographic origin)
Various polyphenols (in mushroom extracts grown on hardwood) Often substrate-accumulated Substrate lot + source

QC implication: substrate lot and strain genetics are both candidate sources of batch variation. A lower-cost readout cannot attribute a shift to either cause; substrate and strain provenance must remain documented variables.

Required documentation fields (cultivation data sheet): - Substrate species / source (e.g., oak species, sawdust grade, lot number, geographic origin, supplier) - Substrate lot identifier (vendor lot, harvest date, treatment history) - Substrate composition characterization (if available — lignin content, ash content, mineral profile, any vendor analytical certificate) - Substrate-accumulated vs biosynthesized origin tag (per the table above; applies on a per-compound basis)

For compounds tagged "substrate-accumulated," the Tier 2 batch QC reading must be paired with substrate-lot documentation to be interpretable. A Tier 2 reading showing 20% drop in quercetin content is uninformative without knowing whether the substrate lot also changed.

See also: Culture configuration treats substrate and medium composition as part of a reproducible biological artifact. The documentation discipline above is the prerequisite QC anchor for any substrate-engineering experiment.

Cross-reference to Sourcing and delivery: product form and biomass do not establish target-compound exposure. Downstream reasoning requires target-specific chemical characterization of the exact batch.

SOP-7 — Substrate Engineering Protocol Matrix

Validation state: Draft and primary-literature-anchored. Tier 3 HPLC validation is required for each candidate species and reagent pair before quantitative use.

This matrix is an idea registry, not a transfer table. Each result belongs to the reported strain, medium, culture format, timing, and assay. A result in one fungus can justify a matched experiment in another; it cannot supply an expected direction or magnitude there. Cultivation studies below are In Vitro evidence for the named configuration. Cross-species, cross-strain, or cross-format application remains Mechanistic Extrapolation until tested.

Target-compound leads

Target Exact source configuration Observed in the source Missing measurement or transfer limit Primary source
Cordycepin C. militaris CM01; solid PDA; 12 g/L L-alanine; 7 d dark plus 3 d light 3.03 mg/g dry weight, approximately 3× the no-alanine control Pentostatin not measured; no liquid- or grain-culture inference Yu 2024, PMC11698586
Cordycepin C. militaris GDMCC5.270; submerged medium with 10 g/L glucose, 3.5 g/L peptone, and 1.5 g/L corn-steep-liquor hydrolysate; 8 d 343.03 ± 15.94 mg/L versus 70.97 ± 5.70 mg/L without hydrolysate, 4.83× Pentostatin not measured; response varied among five strains Chang 2024, PMC10931215
Cordycepin Unaccessioned commercial C. militaris strain; solid Allomyrina dichotoma versus Bombyx mori pupae 89.5 mg/g dry weight on A. dichotoma, 34× the B. mori condition Substrates differ in many components; pentostatin not measured Turk 2022, PMC9627333
Cordycepin Same Turk strain on A. dichotoma with versus without added oleic acid Cordycepin content increased 51.4%; cns1 and cns2 transcripts increased about 3× and 1.8× Supplement dose is not stated in the article text; pentostatin not measured Turk 2022, PMC9627333
Total ganoderic-acid assay G. lucidum CGMCC5.0026; submerged culture; 1.5% microcrystalline cellulose added at 72 h 21.2 versus 11.4 mg/100 mL, reported as an 85.96% increase Individual ganoderic and lucidenic acids not resolved Hu 2017, PMC5395960
Total ganoderic-acid assay Same strain and format; 0.5% D-galactose added at 72 h 20.36 versus 12.42 mg/100 mL, reported as a 63.9% increase Individual compounds not resolved Hu 2017, PMC5395960
Triterpenoid profile Five commercial G. lucidum fruiting bodies per method; wood-log versus substitute cultivation; exact strain unreported Wood-log samples had about 1.2× total triterpenoid peak area and 2.19× combined lucidenic acids. Substitute samples had 13.5× ganosporelactone B. Ganoderic-acid A/alpha favored substitute cultivation; E/O favored wood-log cultivation. Not a controlled within-strain substrate swap; identities were putative untargeted-MS assignments Luo 2024, PMC10879320
Ergothioneine Nine mushroom species; submerged fungal growth medium; 2 mM methionine; 10 d Significant EGT increases in six of nine tested species Species-specific effects differed; the paper does not support a universal fold change Lee 2009, PMC3749454
Ergothioneine Ganoderma neo-japonicum mycelial culture; 4 mM methionine plus 1 g/L yeast extract Approximately 1.7 versus 0.7 mg/L, 2.4×; mycelial growth was inhibited Not evidence for Pleurotus, koji, or solid culture Lee 2009, PMID 18688580
Ergothioneine Wild-type A. oryzae RIB40; solid DPY; 5 d; methionine titration 0.1% methionine produced about 2× the unsupplemented EGT level; 0.8% produced 5.12 mg/g dry weight, while growth declined as methionine concentration increased DPY is not rice koji. The reported 20.03 mg/g and 8× result also required an engineered strain and a different carbon-source/precursor configuration. Wang 2025, PMC12152031
Betulinic acid I. obliquus CFCC 83414; submerged culture; 1.0 g/L oleic acid added on day 6; measured day 13 Dry-mycelium BA increased 223.1% and broth BA 202.0% (3.23× and 3.02× control) Betulin and other triterpenoid ratios not reported for this comparison Lou 2021, PMC8066064
Betulinic acid Same strain; 45 mg/L disrupted A. niger elicitor Positive candidate, but the article's abstract and results assign incompatible magnitudes to biomass and intracellular BA Re-extract figure-level values before using a quantitative expectation Lou 2021, PMC8066064
Betulinic acid Same strain; 1.0 g/L oleic acid plus 45 mg/L elicitor added on day 7 Intracellular BA reached 22.2× control; total BA increased 129.7% (2.30×) The 22.2× intracellular result is not a 22.2× total-yield result Lou 2021, PMC8066064
Betulinic acid Natural I. obliquus conks from different isolates/sites on Alnus incana versus Betula pendula 474–635 versus 20–132 µg/g dry weight; inotodiol ranges were similar, while birch conks contained more polyphenols, flavonols, and glucans Mechanistic Extrapolation: host, isolate, and site are confounded; this is not a within-strain host intervention Drenkhan 2022, PMC9496626
Erinacine C and pathway profile One barcoded private-library H. erinaceus culture; submerged dextrose/oatmeal complex medium versus barley-malt minimal medium; 21 d Erinacine C was about two orders of magnitude higher in complex medium; relative erinacine Q peak area was higher in minimal medium; A and P signals did not differ significantly; tested eri transcripts did not differ significantly Q, A, and P lacked analytical standards, so a quantitative C:Q ratio was not established Doar 2025, PMC11969743

Production-only leads

These rows can improve cultivation or supply, but they do not establish more of a gout-relevant compound.

Response Exact source configuration Observed in the source Limit Primary source
Fruiting-body yield Unaccessioned P. ostreatus strain; sawdust/cottonseed-hull/wheat-bran substrate; 0.04% uridine 362.6 g total yield, 35.3% above control; biological efficiency 73.77%, 19.77% above control Target secondary metabolites were not profiled Tang 2025, PMC12299871
Faster wood-free production H. erinaceus 20190111; 16.3% rice straw, 59.7% corn cob, 20% wheat bran plus minor components First crop arrived 7–9 d sooner. Biological efficiency was 89.14% versus 92.49% for the wood-chip control; fresh yield was also slightly lower. A resource-substitution and cycle-time result, not an erinacine-yield result Lu 2024, PMC11671258

Operational discipline (per SOP-6 four-tier framework):

  1. Candidate registration — preserve the exact source configuration and state what was not measured.
  2. Tier 3 analytical replication — reproduce one matched control/intervention pair and quantify the target, relevant sibling compounds, and growth or biomass.
  3. Tier 2 batch QC development — only after Tier 3 establishes that a lower-cost readout tracks the target in that exact configuration.
  4. Controlled translation — define safety, contamination, exposure, and regulatory gates for any application beyond research cultivation.

Calibration-per-revision discipline: a replicated Tier 3 comparison estimates the effect for the exact configuration. A validated Tier 2 readout may then track later batches only while strain, formulation, culture conditions, extraction, and assay remain within that calibration's scope.

Transfer rule: strain, medium or substrate, supplement, culture format, timing, harvest, and assay form one configuration. Until a transferred configuration is tested, neither the source-study direction nor its magnitude is assumed. See Culture configuration.

SOP-5 — Strain Banking + ITS Authentication

Status: Draft identity workflow. Primer choice and taxonomic acceptance criteria require primary-source and reference-database qualification for the selected species.

Planned method: 1. ITS region amplification (ITS1-5.8S-ITS2) 2. Sanger sequencing 3. Compare against curated reference sequences using a preregistered locus- and species-specific acceptance rule 4. Deposit verified strain in -80°C glycerol stock with documented provenance 5. Define re-verification frequency from the propagation and contamination-control plan

Acceptance criteria: unset until the barcode locus, reference set, ambiguity policy, contamination controls, and confirmatory method are selected.

Cross-references

Open method-development gates

  • For SOP-1, recover the exact cultivation, extraction, and GLPP fractionation methods for the material whose biological result is being tested. Historical Juncao search terms are retrieval aids, not a reason to select that cultivation route.
  • For SOP-3, qualify the method against one exact material without presuming it is the simplest sourcing route.
  • Before SOP-2 co-quantification, obtain lawful research-use reference standards and qualify both analytes in the intended matrix.
  • Use independent operators to estimate method transferability, then set acceptance criteria before result-bearing batch comparisons.